Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Ipamorelin vs Sermorelin
An educational, source-based comparison of Ipamorelin and Sermorelin — how each peptide works, what it's researched for, and what to know before going deeper.
A selective ghrelin/GHS-R1a receptor agonist that stimulates GH release with minimal effect on cortisol, prolactin, or appetite — distinguishing it from older secretagogues like GHRP-6.
- Endogenous GH release without cortisol elevation
- Sleep quality and recovery markers
- Lean tissue retention in catabolic states
- • Generally well tolerated in research; long-term human safety data are limited.
- • Not FDA-approved.
- • Use in sport is prohibited (WADA).
A synthetic 29-amino-acid analog representing the active fragment of endogenous GHRH. Stimulates the pituitary to release GH in a physiologic, pulsatile pattern. Previously FDA-approved (Geref) for pediatric GH deficiency diagnosis before discontinuation for commercial reasons.
- Adult GH deficiency
- Pediatric short stature (historical)
- Sleep quality and body composition in aging
- • No longer commercially available as an FDA-approved drug; available via compounding.
- • Requires physician oversight.
- • Banned in competitive sport.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Ipamorelin | Ipamorelin, the first selective growth hormone secretagogue | European Journal of Endocrinology | 1998 | Characterized selectivity for GH release without affecting ACTH, cortisol, or prolactin. |
| Sermorelin | Sermorelin in adult growth hormone deficiency | Endocrine Practice | 2010 | Reviewed efficacy on body composition, energy, and sleep markers. |
Side-effect & safety grid
- Generally well tolerated in research; long-term human safety data are limited.
- Not FDA-approved.
- Use in sport is prohibited (WADA).
- No longer commercially available as an FDA-approved drug; available via compounding.
- Requires physician oversight.
- Banned in competitive sport.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Ipamorelin vs Sermorelin — Key differences
- Class: Ipamorelin is classified as Growth Hormone Axis, while Sermorelin is Growth Hormone Axis.
- Primary research focus: Ipamorelin — endogenous gh release without cortisol elevation; Sermorelin — adult gh deficiency.
- Tag: Recovery · Sleep vs Growth hormone.